Journal
CURRENT CANCER DRUG TARGETS
Volume 14, Issue 6, Pages 549-556Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009614666140725092430
Keywords
Cancer; E3 ligase; NEDD4; oncogene; target; therapy; ubiquitination
Categories
Funding
- NSFC [81172087]
- NIH [GM089763, GM094777, CA177910]
Ask authors/readers for more resources
The Neuronally expressed developmentally downregulated 4 (NEDD4), functioning largely as an E3 ubiquitin ligase, has been demonstrated to play a critical role in the development and progression of human cancers. In this review, to understand the regulatory mechanism(s) of NEDD4 as well as the signaling pathways controlled by NEDD4, we briefly describe the NEDD4 upstream regulators and its downstream ubiquitin substrates. Moreover, we further discuss its oncogenic roles in human malignancies. Therefore, targeting NEDD4 could be a potential therapeutic strategy for treatment of human cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available